Excalipoint Therapeutics has emerged from stealth with a sizable $68.7 million seed package and a clear goal: build a new generation of T cell-based cancer therapies for tumors that remain notoriously hard to treat.
The Shanghai-based startup’s financing was structured in two parts, beginning with a $41 million launch round when the company was founded in August 2025, followed by a $27.7 million extension that drew support from MPCi and Centurium Capital. Lilly Asia Ventures joined the extension, alongside Eisai Innovation, underscoring continued investor appetite for engineered immuno-oncology platforms in China.
At the center of the company’s strategy is a pipeline of six assets it believes could stand out in a crowded field of bispecific and next-generation T cell engagers. The lead program, EXP011, is a tri-specific antibody designed to recognize DLL3, CD3 and 4-1BB. Excalipoint is developing it for small cell lung cancer and neuroendocrine tumors, two indications where treatment options are limited and durable responses remain elusive.
The company has already moved EXP011 into the clinic, with a Phase 1/2 study underway and first patient dosing completed in October 2025. That early clinical momentum may help Excalipoint generate human data faster as it works to validate both safety and target engagement.
Another disclosed program, EXP012, also uses a tri-specific format and is intended to bind CDH17, CD3 and 4-1BB. The candidate is being positioned for colorectal, gastric and pancreatic cancers, reflecting the company’s interest in tumors with substantial unmet need and limited immunotherapy penetration. A third candidate, EXP016, is aimed at difficult solid tumors, though the company has not yet revealed its molecular targets.
Beyond its drug candidates, Excalipoint is also promoting a set of proprietary technologies designed to support its platform. These include TOPAbody for constructing tri-specific molecules, T-Cell Immune Shield for improving specificity and potency, and TCE Probody for potentially opening up targets that have been difficult to drug with conventional approaches.
CEO Lei Fang, who previously held leadership roles at Lepu Biopharma and I-Mab Biopharma, framed the company’s launch as a combination of scientific design and China’s development speed. That combination has become increasingly attractive to global biopharma, as China continues to offer dense patient pools, fast clinical execution and a more streamlined regulatory environment than many Western markets.
For investors and drug developers alike, Excalipoint’s debut reflects a broader trend: growing confidence that China can do more than manufacture or run trials for global programs. It is increasingly becoming a source of novel oncology innovation, especially in areas like cell therapies, radioconjugates and engineered antibodies where rapid iteration can create an edge.
Whether Excalipoint’s tri-specific approach can translate into differentiated clinical outcomes remains to be seen, but the company now has the capital, platform and first-in-human program needed to test that thesis.
